EUVIMEDEUVIMED entdecken
Crossref

A priori optimization of levofloxacin dose regimen based on a population pharmacokinetics model

Emmanuel Enard iD, Matthieu Grégoire iD, Éric Dailly, Ronan Le Floch, Karim Lakhal, Antoine Roquilly, Emmanuel Canet, David Boutoille iD, Louise Ruffier d'Epenoux, Stéphane Corvec iD, Raphaël Lecomte iD, Ronan Bellouard iD und 1 weitere

Journal of Antimicrobial Chemotherapy · 2025

DOI: 10.1093/jac/dkaf273 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Emmanuel Enard und 12 weiteren Autor:innen. Beteiligte Einrichtung: Nantes Université, CHU Nantes, Pharmacologie Clinique, Nantes F-44000, France. Hauptthemen laut MEDLINE: Levofloxacin, Anti-Bacterial Agents. Die Arbeit nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Levofloxacin is a broad-spectrum fluoroquinolone with pharmacokinetic characteristics that facilitate its use in many types of infections.

Objectives

To develop a population pharmacokinetics (PK) model of levofloxacin and to identify covariates influencing its PK, to determine the best dose regimens for pharmacodynamic target achievement. Patients and methods Patients treated with levofloxacin were retrospectively included from December 2014 to February 2021. The population PK analysis was performed using Pmetrics. Multiple covariates were tested: age, height, weight, ideal weight, BMI, body surface area (BSA), plasma protein and creatinine levels, and absolute glomerular filtration rate (aGFR) calculated from the chronic kidney disease-epidemiology formula and BSA. Dosing simulations were performed for all combinations of covariates and MIC values. The AUC0–24/MIC ratio targets were 50 for Streptococcus pneumoniae and 125 for other bacterial species.

Results

A total of 39 patients were included, of which 23 patients were hospitalized in ICUs. The population PK analysis was performed on 175 plasma concentrations of levofloxacin. A two-compartment model best described levofloxacin PK with three covariates: aGFR for the elimination rate constant and both plasma protein level and BSA for the central compartment volume. Tables with proposed dose regimens according to patient covariates and pharmacodynamic targets values are provided.

Conclusions

This study provided a priori dose regimen adaptation based on a population PK model for levofloxacin. For patients with increased renal function or infection by high MIC bacteria, the pharmacodynamic target could not be reliably achieved with standard dosages.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LevofloxacinAnti-Bacterial AgentsHumansMaleFemaleAgedMiddle AgedRetrospective StudiesMicrobial Sensitivity TestsAged, 80 and overAdultStreptococcus pneumoniaeGlomerular Filtration Rate

Substanzen

LevofloxacinAnti-Bacterial Agents

Autor:innen und Institutionen

  • Nantes Université, CHU Nantes, Pharmacologie Clinique, Nantes F-44000, France.
  • Nantes Université, CHU Nantes, Cibles et Médicaments des Infections et de L'Immunité, IICiMed, UR 1155, Nantes F-44000, France.
  • Nantes Université, CHU Nantes, Anesthésie-Réanimation Chirurgicale, Nantes F-44000, France.
  • Nantes Université, CHU Nantes, Anesthésie-Réanimation Chirurgicale, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, Nantes F-44000, France.
  • Nantes Université, CHU Nantes, Médecine Intensive et Réanimation, Nantes F-44000, France.
  • Nantes Université, CHU Nantes, INSERM, Maladies Infectieuses et Tropicales, CIC 1413, Nantes F-44000, France.

ORCID-Profile: Emmanuel Enard, Matthieu Grégoire, David Boutoille, Stéphane Corvec, Raphaël Lecomte, Ronan Bellouard

Zitieren

APA

Enard, E., Grégoire, M., Dailly, É., Le Floch, R., Lakhal, K., Roquilly, A., Canet, E., Boutoille, D., Ruffier d'Epenoux, L., Corvec, S., Lecomte, R., Bellouard, R., & Nantes Anti-Microbial Agents PK/PD (NAMAP) study group (2025). A priori optimization of levofloxacin dose regimen based on a population pharmacokinetics model. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf273

Vancouver

Enard E, Grégoire M, Dailly É, Le Floch R, Lakhal K, Roquilly A, et al. A priori optimization of levofloxacin dose regimen based on a population pharmacokinetics model. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkaf273

BibTeX
@article{Enard2025,
  author = {Enard, Emmanuel and Grégoire, Matthieu and Dailly, Éric and Le Floch, Ronan and Lakhal, Karim and Roquilly, Antoine and Canet, Emmanuel and Boutoille, David and Ruffier d'Epenoux, Louise and Corvec, Stéphane and Lecomte, Raphaël and Bellouard, Ronan and Nantes Anti-Microbial Agents PK/PD (NAMAP) study group, Nantes Anti-Microbial Agents PK/PD (NAMAP) study group},
  title = {A priori optimization of levofloxacin dose regimen based on a population pharmacokinetics model},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  doi = {10.1093/jac/dkaf273}
}
Kostenlos starten →